DUSA Completes Enrollment For Phase IIb Trial Of Levulan(R) Photodynamic Therapy For Moderate To Severe Acne

April 01st, 2008 | Category: Dermatology

DUSA Pharmaceuticals, Inc.(R) (NASDAQ GM:DUSA), is pleased to announce that the acne Phase IIb trial has achieved its goal of 260 participants, thus completing enrollment. The study’s objective is to determine and compare the safety and efficacy of multiple broad area photodynamic

therapy (PDT) treatments with Levulan® Kerastick® in combination with BLU-U® grade blue light versus use of the BLU-U alone in patients with moderate to severe facial acne vulgaris.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Isolagen, Inc. Completes Enrollment In Isolagen Therapy(TM) Phase II/III Acne Scar Study
  • Isolagen Initiates Phase III Clinical Program To Investigate Isolagen Therapy(TM) For The Treatment Of Acne Scars
  • Symbollon Pharmaceuticals Completes Phase III Pivotal Trial For IoGen
  • A.P. Pharma Completes Enrollment In Phase 3 Trial Of APF530
  • Metabolex Completes Patient Enrollment In Phase 2 Trial Of MBX-8025 For Treatment Of Dyslipidemia

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.